Patents by Inventor Aude Sirven

Aude Sirven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10407695
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 10, 2019
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Patent number: 10288143
    Abstract: The invention relates to a shock absorber (1), in particular for a motor vehicle, which comprises: a cylinder (2) containing a hydraulic fluid; a main piston (4) actuated by a rod (3), defining in the cylinder a first main chamber (5) and a second main chamber (6), the second main chamber containing the rod; a hydraulic fluid vessel (24); and a valve (11) placed in the flow of the hydraulic fluid between the first main chamber and the second main chamber or between the first main chamber and the vessel. The valve comprises a mobile gate (14) engaging with a seat (13), a spring (20) tending to urge the gate against the seat thereof, and a mobile valve piston (17, 78), defining a first valve chamber (18, 82) and a second valve chamber (19, 83) in the valve, said mobile valve piston being capable of compressing the spring and closing the gate.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: May 14, 2019
    Inventors: Jacques Sirven, Marc Sirven, François Sirven, Aude Sirven, Alain Bordier
  • Publication number: 20190119699
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 24, 2018
    Publication date: April 25, 2019
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Publication number: 20180346928
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 24, 2018
    Publication date: December 6, 2018
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Patent number: 9238824
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 19, 2016
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Publication number: 20150191745
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: February 4, 2015
    Publication date: July 9, 2015
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Publication number: 20150011006
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 8, 2015
    Applicants: Institut Pasteur, Institut National De La Sante Et De La Recherche Medicale, Centre National De La Recherche Scientifique
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Publication number: 20030194392
    Abstract: The present ivention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: April 10, 2002
    Publication date: October 16, 2003
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt